London Keeps the CE Stamp as Brussels Modernises Clinical Trials

European health regulation saw moves on both sides of the English Channel. The European Medicines Agency (EMA) opened a consultation seeking stakeholder feedback on platform trials—adaptive clinical trial designs that allow researchers to evaluate multiple treatments simultaneously within a single overarching structure. Meanwhile, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) announced it will recognise European CE-marked medical devices indefinitely.

For medical device manufacturers, the UK’s decision removes the looming headache of duplicate testing and paperwork to place goods on British shelves. A CE mark—the familiar European badge showing a product meets EU safety, health, and environmental rules—will continue to suffice in Britain without a countdown clock. For drug developers and patients, modernised guidance on platform trials promises faster, more flexible clinical trials that can test several therapies at once instead of running separate, costly trials for each.

There is a quiet, institutional irony in London deciding that the simplest path forward on medical hardware is to keep relying on European conformity stickers forever. Brussels civil servants spend years refining technical standards, often accused of bureaucratic density; yet regulatory gravity remains hard to escape. While the EU’s Amsterdam-based medicines watchdog works through the finer procedural points of complex clinical trial methodologies, the UK has concluded that rewriting European device certification rules from scratch is an exercise best left indefinitely deferred.

The EMA will collect feedback from researchers, pharmaceutical companies, and regulators to shape its final guidelines on platform trials. Medical technology firms can continue supplying the UK market under their existing European CE certifications without fear of an arbitrary expiry date.